[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Dominican Republic\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":420},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,42,64,87,118,147,170,196,224,249,284,314,340,367,397],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100596349","a-clinical-study-of-mk-8527-to-prevent-human-immunodeficiency-virus-type-1-hiv-1-mk-8527-011-100596349",false,"NCT07044297","A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)","A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Is confirmed HIV-uninfected based on negative HIV-1\u002FHIV-2 test results\n* Is a cisgender man, transgender woman (assigned male sex at birth), transgender man (assigned female sex at birth), or gender nonbinary person\n* Has had condomless receptive anal sex in the 12 months prior to screening (not including sex occurring in a mutually monogamous relationship) and has at least 1 of the following: receptive anal sex with 2 or more partners in the 3 months prior to screening (regardless of condom use), rectal or urethral gonorrhea or chlamydia or incident syphilis in the 6 months prior to screening, or any self-reported stimulant drug use with sex in the 3 months prior to screening\n* Weighs ≥35 kg\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has hypersensitivity or other contraindication to any component of the study interventions\n* Has evidence of acute or chronic hepatitis B infection\n* Has a history of malignancy within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer, or in situ anal or cervical cancers\n* Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product at any time\n* Is receiving or is anticipated to require any prohibited therapies from 30 days prior to Day 1 through the study duration\n* Has received an HIV vaccine at any time (ie, through past participation in an investigational clinical study) or monoclonal antibodies to HIV within 12 months before Day 1\n* Is expecting to donate eggs at any time during the study",true,"ALL","16 Years",{"count":20,"type":21},4390,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection.\n\nThe goals of this study are to learn:\n\n* If taking MK-8527 once a month works to prevent HIV-1 infection as well as or better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day\n* About the safety of MK-8527 and if people tolerate it",[27,28],"Human Immunodeficiency Virus (HIV)","HIV Pre-Exposure Prophylaxis","RECRUITING","2026-08-21",{"date":32,"type":33},"2026-08-24","ACTUAL",{"date":35,"type":33},"2025-07-31",{"date":37,"type":21},"2027-07-22",{"name":39,"class":40},"Merck Sharp & Dohme LLC","INDUSTRY",81,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100549191","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-tulisokibart-mk-7240-in-participants-with-moderate-to-severe-crohns-disease-mk-7240-008-100549191","NCT06430801","A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderately to Severely Active Crohn's Disease","The main inclusion and exclusion criteria include but are not limited to the following:\n\nInclusion Criteria:\n\n* Has had a diagnosis of Crohn's disease (CD) at least 3 months before study.\n* Has moderately to severely active CD.\n* Demonstrated inadequate response, loss of response, or intolerance to one or more of the following categories of drugs: oral locally acting steroids, systemic steroids, immunomodulators, biologic and\u002For small molecule advanced therapies.\n* Adolescent participants ≥16 and \\\u003C18 years of age can participate if approved by the country or regulatory\u002Fhealth authority.\n\nExclusion Criteria:\n\n* Has diagnosis of ulcerative colitis (UC) or indeterminate colitis.\n* Has CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and\u002For ileal involvement.\n* Currently has any of the following complications of CD: suspected or diagnosed with intra-abdominal or perianal abscess, known symptomatic stricture or colonic stenosis not passable in endoscopy, fulminant colitis, toxic megacolon, or any other manifestation that might require surgery while enrolled in the study.\n* Has current stoma or need for colostomy or ileostomy.\n* Is missing \\>2 segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum.\n* Has been diagnosed with short gut or short bowel syndrome, or any other uncontrolled chronic diarrhea besides CD.\n* Has surgical bowel resection within 3 months of study.\n* Has prior or current gastrointestinal dysplasia.\n* Has chronic infection requiring ongoing antimicrobial treatment.\n* Has a history of cancer (except fully treated non-melanoma skin cell cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for \\\u003C5 years.\n* Is infected with Hepatitis B virus (HBV), Hepatitis C virus (HCV), or human immunodeficiency virus (HIV).\n* Has active tuberculosis.\n* Has confirmed or suspected coronavirus disease of 2019 (COVID-19) infection.\n* Prior exposure to tulisokibart (MK-7240, PRA023) or another anti-tumor necrosis factor-like cytokine 1A (TL1A) antibody (Ab).","80 Years",{"count":51,"type":21},1200,[24],"The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\\\u003C150, US\u002FFDA) or per stool frequency and abdominal pain score (EU\u002FEMA) and in the proportion of participants achieving endoscopic response at Week 52 (US\u002FFDA and EU\u002FEMA), and that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\\\u003C150, US\u002FFDA) or per stool frequency and abdominal pain score (EU\u002FEMA) and in the proportion of participants achieving endoscopic response at Week 12 (US\u002FFDA and EU\u002FEMA). Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\\\u003C150, US\u002FFDA) or stool frequency and abdominal pain score (EU\u002FEMA) and in the proportion of participants achieving endoscopic response at Week 12 (US\u002FFDA and EU\u002FEMA).",[55],"Crohn's Disease","2026-08-20",{"date":30,"type":33},{"date":59,"type":33},"2024-06-05",{"date":61,"type":21},"2029-11-12",{"name":39,"class":40},499,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100579098","phase-3-a-study-to-assess-the-efficacy-and-safety-of-induction-and-maintenance-therapy-with-afimkibart-ro7790121-in-participants-with-moderately-to-severely-active-crohns-disease-100579098","NCT06819878","A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease","A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease","SIBERITE-1","Inclusion Criteria:\n\n* Confirmed diagnosis of CD\n* Moderately to severely active CD\n* Bodyweight \\>= 40 kilogram (kg)\n* Demonstrated inadequate response, loss of response and\u002For intolerance to at least one protocol-specified conventional or advanced CD therapy\n* Males and females of childbearing potential must meet protocol criteria for contraception requirements\n\nExclusion Criteria:\n\n* Current diagnosis of ulcerative colitis (UC) or indeterminate colitis, ischemic colitis, infectious colitis, radiation colitis, microscopic colitis\n* Participant with a history of \\>= 3 bowel resections (\\> 2 missing segments of the 5 following segments: terminal ilelium, right colon, transverse colon, sigmoid and left colon, and rectum)\n* Diagnosis of short gut or short bowel syndrome\n* Presence of an ileostomy, colostomy or ileoanal pouch\n* Participants with symptomatic bowel strictures, fulminant colitis, or toxic megacolon\n* Presence of abdominal or perianal abscess\n* Presence of rectovaginal, enterovaginal, high output enterocutaneous fistula, enterovesical fistulas or perianal fistulas with \\>3 openings\n* Current diagnosis or suspicion of primary sclerosing cholangitis\n* Pregnancy or breastfeeding, or intention of becoming pregnant during the study\n* Any past or current evidence of cancer of gastrointestinal tract, definite low-grade or high-grade colonic dysplasia\n* History of non-gastrointestinal cancer, with the exception of adequately treated non-metastatic basal cell or squamous cell skin cancer or in situ cervical cancer\n* Evidence of infection with Clostridioides difficile (C. difficile; formerly known as Clostridium difficile), cytomegalovirus (CMV), human immunodeficiency virus (HIV), Hepatitis B (HBV), Hepatitis C (HCV) during screening\n* Has evidence of active tuberculosis (TB), latent TB not successfully treated (per local guidance) or inadequately treated TB\n* Has received protocol-specified prohibited medicines, including known exposure to any type of anti-TL1A therapy",{"count":73,"type":21},600,[24],"This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).",[77],"Moderately to Severely Active Crohns Disease","2026-08-18",{"date":56,"type":33},{"date":81,"type":33},"2025-03-17",{"date":83,"type":21},"2033-12-31",{"name":85,"class":40},"Hoffmann-La Roche",373,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":117},"100649993","continuous-glucose-monitoring-in-high-risk-children-and-youth-with-type-1-diabetes-in-the-dominican-republic-100649993","NCT07742306","Continuous Glucose Monitoring in High-Risk Children and Youth With Type 1 Diabetes in the Dominican Republic","The Effects of Continuous Glucose Monitoring Interventions in High-Risk Children and Youth With Type 1 Diabetes in the Dominican Republic","Inclusion Criteria:\n\n* HbA1c \\>9.0%\n* Age range: 10-19 years\n* Disposition and availability for patients and families to attend scheduled provider meetings, as well as general diabetic educational and psychological support meetings throughout the whole study. Namely, meeting every 2 weeks for the first 3 months and then every 4 weeks until completion of study for next 12 months.\n* Willingness and ability to provide signed voluntary consent form. Date and signature is requested however based on literacy levels a patient can provide consent verbally as long as there is a witness who is 18 years or older and demonstration of acknowledgement of information provided.\n\nExclusion Criteria:\n\n* Diagnosis of T1D within the past 12 months\n* Previous or current use of CGM like FreeStyle Libre 2, Dexcom (G6, G7), or similar devices from other companies not mentioned\n* Current use of continuous insulin pump in combination with CGM use at present or prior to study\n* Residence location with greater than 3 hours of travel time distance from each health center in setting of cost and feasibility for families to travel on frequent necessary basis\n* Current steroid therapy orally or intravenously.\n* Medical comorbidities including chronic renal disease, hemoglobinopathies, leukemia, hematologic or oncologic conditions that can affect glycemia\n* Pregnancy","10 Years","19 Years",{"count":97,"type":21},40,"OBSERVATIONAL","The goal of this pilot longitudinal study is to investigate whether intermittent use of the Dexcom G7 continuous glucose monitor, together with pediatric endocrinology follow-up, diabetes education, and psychological support, can improve glucose control in children and adolescents with high-risk type 1 diabetes in the Dominican Republic.\n\nThe study will include 40 participants, 10 to 19 years of age, from two pediatric diabetes care centers. Participants will use the Dexcom G7 during two short monitoring periods in the early part of the study. Each participant will use six sensors in total. Between and after these monitoring periods, participants will return to their usual finger-stick glucose monitoring with a glucometer. Participants and their families will also attend scheduled medical visits, diabetes education sessions, and psychological support sessions.\n\nStudy information will be collected from medical records, laboratory results, Dexcom Clarity reports, participant glucose logs, study forms, and questionnaires.\n\nThe study will assess changes in HbA1c, time in range, average glucose, glucose variability, low and high blood glucose episodes, adverse events, diabetes-related distress, fear of hypoglycemia, and satisfaction with glucose monitoring.",[101],"Type 1 Diabetes (T1D)",[103,104,105,106],"Continous glucose monitoring (CGM)","Youth","Dominican Republic","Intermittent CGM","2026-08-11",{"date":109,"type":33},"2026-08-13",{"date":111,"type":33},"2025-11-14",{"date":113,"type":21},"2027-12",{"name":115,"class":116},"Life for a Child Program, Diabetes Australia","OTHER",3,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":16,"sex":17,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100578041","phase-3-a-study-on-the-immune-response-and-safety-of-the-second-dose-of-an-investigational-chickenpox-vaccine-when-given-to-healthy-children-3-months-after-a-first-dose-at-12-to-15-months-of-age-100578041","NCT06806137","A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","A Phase 3a, Observer-blind, Randomized, Controlled, Study to Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, When Given as a Second Dose to Healthy Children, 3 Months After the Administration of a First Dose at 12 to 15 Months of Age","Inclusion Criteria:\n\n* Participant's parent(s)\u002FLegally acceptable representative (LAR)(s), who, in the opinion of the investigator, can and will comply with the requirements of the protocol\n* Written or witnessed\u002Fthumb printed informed consent obtained from the participant's parent(s)\u002FLAR(s) prior to performance of any study-specific procedure.\n* Healthy participants as established by medical history and clinical examination before entering into the study.\n* A male or female between, and including, 12 to 15 months of age (i.e., from the day of 1 year birthday until the day before 16 months of age) at the time of the administration of the first study interventions.\n* Only for children in countries where PCV is recommended at 12 to 15 months of age as per national immunization schedule and provided as part of the study interventions: participant who previously received the primary series of PCV in the first year of life with last dose at least 60 days prior to study entry.\n\nExclusion Criteria:\n\n* History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.\n* Hypersensitivity to latex.\n* Major congenital defects, as assessed by the investigator.\n* Recurrent history of uncontrolled neurological disorders or seizures.\n* History of varicella disease.\n* Active untreated tuberculosis.\n* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.\n* Use of any investigational or non-registered product (drug, vaccine or invasive medical device) other than the study interventions during the period beginning 30 days before the first dose of study interventions (Day -29 to Day 1), or their planned use during the study period.\n* Planned administration of a vaccine in the period starting 30 days before the first dose and ending 43 days after the second dose of study interventions administration (Visit 3), with the exception of inactivated influenza vaccine which may be given at any time during the study and administered at a different location than the study interventions.\n* Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and\u002For planned use of long-acting immune-modifying treatments at any time up to the end of the study.\n\n  * Up to 90 days prior to the study intervention administration:\n\n    i) For corticosteroids, this will mean prednisone equivalent \\>=0.5 mg\u002Fkg\u002Fday with maximum of 20 mg\u002Fday for pediatric participants. Inhaled and topical steroids are allowed.\n\nii) Administration of immunoglobulins and\u002For any blood products or plasma derivatives.\n\n* Up to 180 days prior to study interventions administration: long acting immune-modifying drugs including among others immunotherapy (e.g., tumor necrosis factor-inhibitors), monoclonal antibodies (except the ones not interfering with the immune response to the study vaccinese.g., nirsevimab), antitumoral medication.\n* Previous vaccination against measles, mumps, and rubella.\n* Previous vaccination against hepatitis A virus.\n* Previous vaccination against varicella virus.\n* Only for children in countries where PCV is recommended at 12 to 15 months of age as per national immunization schedule and provided as part of the study interventions, participant who previously received a booster dose of any PCV.\n* Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug\u002Finvasive medical device).\n* Child in care.\n* Any study personnel's immediate dependents, family, or household members.\n* Participants with the following high-risk individuals in their household:\n\n  i) Immunocompromised individuals. ii) Pregnant women without documented history of varicella. iii) Newborn infants of mothers without documented history of varicella. iv) Newborn infants born less than (\\\u003C) 28 weeks of gestation.","12 Months","15 Months",{"count":73,"type":21},[24],"The purpose of this study is to evaluate the immune response and safety of GSKs investigational varicella vaccine (VNS Vaccine) compared to an already approved varicella vaccine, Varivax (VV), when administered as second dose to healthy children. 3 months after first dose at 12 to 15 months. The study will be conducted in children who have not previously contracted varicella or received a varicella vaccination.",[131],"Chickenpox",[133,134,135,136],"Chicken pox","Investigational varicella vaccine (VNS) Varicella","Varivax (VV)","Healthy Children","2026-05-27",{"date":139,"type":33},"2026-05-29",{"date":141,"type":33},"2025-05-15",{"date":143,"type":21},"2027-05-03",{"name":145,"class":40},"GlaxoSmithKline",6,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":16,"sex":17,"minAge":125,"maxAge":126,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},"100573004","phase-3-a-study-on-the-immune-response-and-safety-of-an-investigational-chickenpox-vaccine-when-given-to-healthy-children-12-to-15-months-of-age-100573004","NCT06740630","A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age","A Phase 3a, Observer-blind, Randomized, Controlled Study to Demonstrate Lot-to-lot Consistency and Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, Administered as a First Dose to Healthy Children 12 to 15 Months of Age","Inclusion Criteria:\n\n* Participant's parent(s) Legally acceptable representatives \u002F(LAR\\[s\\]), who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiaries, return for follow-up visits).\n* Written or witnessed\u002Fthumb printed informed consent obtained from the participant's parent(s)\u002FLAR(s) prior to performance of any study-specific procedure.\n* Healthy participants as established by medical history and clinical examination before entering into the study.\n* A male or female between, and including, 12 to 15 months of age (i.e., from the day of 1-year birthday until the day before 16 months of age) at the time of the administration of study interventions.\n* Only for children in countries where PCV is recommended at 12 to 15 months of age as per national immunization schedule and provided as part of the study interventions:\n\n  * Participant who previously received the primary series of PCV in the first year of life with last dose at least 60 days prior to study entry.\n\nExclusion Criteria:\n\n* History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.\n* Hypersensitivity to latex.\n* Major congenital defects, as assessed by the investigator.\n* Recurrent history of uncontrolled neurological disorders or seizures.\n* History of varicella disease.\n* Active untreated tuberculosis.\n* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.\n* Use of any investigational or non-registered product (drug, vaccine or invasive medical device) other than the study interventions during the period beginning 30 days before the dose of study interventions administration (Day -29 to Day 1), or their planned use during the study period.\n* Planned administration of a vaccine in the period starting 30 days before the dose and ending 43 days after the dose of study interventions administration\\* (Visit 2) with the exception of inactivated influenza vaccine which may be given at any time during the study and administered at a different location than the study interventions.\n\nAny other age-appropriate vaccine may be given starting at Visit 2 and anytime thereafter.\n\n\\*If emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is organized by public health authorities outside the routine immunization program, the time period described above can be reduced provided it is used according to the local governmental recommendations and sponsor is notified\n\n* Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and\u002For planned use of long-acting immune modifying treatments at any time up to the end of the study.\n\n  * Up to 90 days prior to the study intervention administration:\n  * For corticosteroids, this will mean prednisone equivalent \\>=0.5 mg\u002Fkg\u002Fday with maximum of 20 mg\u002Fday for pediatric participants. Inhaled and topical steroids are allowed.\n  * Administration of immunoglobulins and\u002For any blood products or plasma derivatives.\n  * Up to 180 days prior to study interventions administration: long acting immune-modifying drugs including among others immunotherapy (e.g., tumor necrosis factor-inhibitors), monoclonal antibodies (except the ones not interfering with the immune response to the study vaccines, e.g., nirsevimab), antitumoral medication.\n* Previous vaccination against measles, mumps, and rubella.\n* Previous vaccination against hepatitis A virus.\n* Previous vaccination against varicella virus.\n* Only for children in countries where PCV is recommended at 12 to 15 months of age as per national immunization schedule and provided as part of the study interventions, participant who previously received a booster dose of any PCV.\n* Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug\u002Finvasive medical device).\n* Child in care.\n* Any study personnel's immediate dependents, family, or household members.\n* Participants with the following high-risk individuals in their household:\n\n  * Immunocompromised individuals.\n  * Pregnant women without documented history of varicella.\n  * Newborn infants of mothers without documented history of varicella.\n  * Newborn infants born less than (\\\u003C) 28 weeks of gestation.",{"count":155,"type":21},1840,[24],"The purpose of this study is to assess the consistency of immune response to three different lots of GSK's investigational varicella vaccine (VNS Vaccine), and to compare the safety and immune response of VNS vaccine to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted in healthy children aged 12 to 15 months, who have neither contracted varicella nor received a varicella vaccination.",[131],[133,160,161,162,136],"VNS","Varicella","Varivax",{"date":139,"type":33},{"date":165,"type":33},"2025-01-10",{"date":167,"type":21},"2027-05-17",{"name":145,"class":40},97,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":176,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":195},"100604259","feasibility-study-of-an-accommodating-iol-design-100604259","NCT07147192","Feasibility Study of an Accommodating IOL Design","Key Inclusion Criteria:\n\n* Able to understand and sign an Informed Consent Form.\n* Willing and able to attend all scheduled study visits required per protocol.\n* Diagnosed with bilateral cataracts requiring removal by phacoemulsification.\n* Preoperative corneal astigmatism equal to or less than 1.50 diopter (D) in both eyes.\n* Other protocol-defined inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Women of childbearing potential who are pregnant, intend to become pregnant during the study, or are breastfeeding.\n* Taking medications that could increase risk or may affect accommodation.\n* Eye conditions as specified in the protocol, including glaucoma or ocular hypertension.\n* Medical conditions that could increase operative risk as specified in the protocol.\n* Other protocol-defined exclusion criteria may apply.","22 Years",{"count":178,"type":21},85,[180],"NA","The purpose of this clinical study is to assess safety and explore usability and effectiveness of the test product, AAL-FAIOL. This study will be conducted in Central America.",[183],"Aphakia",[185],"Cataract","2026-05-18",{"date":188,"type":33},"2026-05-19",{"date":190,"type":33},"2025-12-03",{"date":192,"type":21},"2028-01",{"name":194,"class":40},"Alcon Research",4,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":203,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":223},"100611946","phase-3-study-of-a-single-dose-of-a-21-valent-pneumococcal-conjugate-vaccine-in-children-and-adolescents-with-sickle-cell-disease-100611946","NCT07247188","Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease","A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease","Inclusion Criteria:\n\nAGE\n\n* Aged 2 to 17 years on the day of inclusion.\n\nTYPE OF PARTICIPANT AND DISEASE CHARACTERISTICS\n\n* Participants who have a documented diagnosis of sickle cell disease (SCD) in their medical record.\n\nSEX, CONTRACEPTIVE\u002FBARRIER METHOD AND PREGNANCY TESTING REQUIREMENTS\n\n* A participant is eligible to participate if the participant is not pregnant or breastfeeding and one of the following conditions applies:\n\n  * Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be pre-menarchal or surgically sterile. OR\n  * Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 4 weeks after study intervention administration. A participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 25 hours before the study intervention.\n\nINFORMED CONSENT\n\n* Assent form has been signed and dated by the participant (based on local regulations), and, if applicable, informed consent form has been signed and dated by the parent(s) or another legally acceptable representative (LAR) and by an independent witness, if required by local regulations.\n\nOTHER INCLUSIONS\n\n* Participant and parent(s)\u002FLAR are able to attend all scheduled visits and to comply with all study procedures.\n\nExclusion Criteria:\n\nMEDICAL CONDITIONS\n\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy.\n* History of microbiologically confirmed S. pneumoniae infection or disease.\n* History of seizure or significant stable or progressive neurological disorders such as inflammatory nervous system diseases, encephalopathy, and cerebral palsy.\n* Known systemic hypersensitivity to any of the study interventions components, or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances.\n* Laboratory-confirmed thrombocytopenia, or known thrombocytopenia, as reported by the parent\u002FLAR, contraindicating intramuscular (IM) injection.\n* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM injection.\n* Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion.\n* Moderate or severe acute illness\u002Finfection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C \\[≥ 100.4°F\\]) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.\n\nFor children\u002Fadolescents (6 to 17 YoA) only\n\n* Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion.\n\nPRIOR\u002FCONCOMITANT THERAPY\n\n* Receipt of at least one dose of 20vPCV.\n* For children aged \\\u003C 6 years: receipt of \\\u003C 3 doses of pneumococcal conjugate vaccine or any dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23).\n* For children and adolescents aged ≥ 6 years: receipt of PPSV23 \\\u003C 5 years before study vaccination or last PCV dose \\\u003C 8 weeks before study vaccination.\n* Receipt of any vaccine in the 4 weeks preceding the study intervention administration or planned receipt of any vaccine in the 4 weeks following the study intervention administration, except for US licensed influenza vaccination, which may be received at least 2 weeks before or 2 weeks after study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines, as applicable per local recommendations.\n* Receipt of immune globulins, blood or blood-derived products in the past 3 months.\n* Receipt of an oral or injectable antibiotic therapy for any acute illness within 72 hours prior to the first blood draw.\n\nPRIOR\u002FCONCURRENT CLINICAL STUDY EXPERIENCE\n\n* Participation at the time of study enrollment (or in the 6 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.\n\nOTHER EXCLUSIONS For children (2 to 5 YoA) only\n\n* Being in an emergency setting.\n* Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study.\n\nFor children\u002Fadolescents (6 to 17 YoA) only\n\n* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.\n* Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","2 Years","17 Years",{"count":206,"type":21},100,[24],"The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called \"antibodies\" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2 to 17 years with sickle cell disease who had received or not a previous vaccination with pneumococcal conjugate or pneumococcal polysaccharide vaccine.",[210],"Sickle Cell Disease",[210,212,213],"Pneumococcal Vaccine","Pneumococcal Conjugate Vaccine","2026-04-13",{"date":216,"type":33},"2026-04-15",{"date":218,"type":33},"2026-01-20",{"date":220,"type":21},"2027-01-07",{"name":222,"class":40},"Sanofi",7,{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":231,"targetDuration":125,"studyType":98,"phases":4,"briefSummary":233,"conditions":234,"keywords":239,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":248},"100084590","international-collaborative-gaucher-group-icgg-gaucher-disease-registry--pregnancy-sub-registry-100084590","NCT00358943","International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry","Gaucher Disease Registry Protocol","Inclusion Criteria:\n\nICGG Gaucher Registry\n\n* All patients with a confirmed diagnosis of Gaucher disease are eligible for inclusion in the Registry. Confirmed diagnosis is defined as a documented β-glucocerebrosidase deficiency and\u002For mutation in the β-glucocerebrosidase gene.\n* For all patients, appropriate patient authorization will be obtained.\n\nGaucher Pregnancy Sub-registry:\n\n* be enrolled in the ICGG Gaucher Registry.\n* be pregnant, or have been pregnant with appropriate medical documentation available.\n* provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed.\n\nExclusion Criteria:\n\n\\- No exclusion criteria for participation in the ICGG Gaucher Registry and Sub-registry.",{"count":232,"type":21},12000,"The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.\n\nThe objectives of the Registry are:\n\n* To enhance understanding of the variability, progression, identification, and natural history of Gaucher disease, with the ultimate goal of better guiding and assessing therapeutic intervention.\n* To assist the Gaucher medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.\n* To characterize the Gaucher disease population.\n* To evaluate the long-term effectiveness of imiglucerase and of eliglustat.\n\nGaucher Pregnancy Sub-registry: The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Gaucher disease during pregnancy, regardless of whether they receive disease-specific therapy. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.",[235,236,237,238],"Gaucher Disease","Cerebroside Lipidosis Syndrome","Glucocerebrosidase Deficiency Disease","Glucosylceramide Beta-Glucosidase Deficiency Disease",[235,237],{"date":241,"type":33},"2026-04-14",{"date":243,"type":33},"1991-04-01",{"date":245,"type":21},"2034-01-31",{"name":247,"class":40},"Genzyme, a Sanofi Company",318,{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":17,"minAge":256,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":259,"conditions":260,"keywords":267,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":5},"100613110","epidemiology-and-processes-of-care-for-renal-replacement-therapy-in-acute-kidney-injury-in-latin-america-100613110","NCT07262320","Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America","LATAM-AKID","Inclusion Criteria:\n\n* Adult patient (≥18) admitted to the ICU\n* First ICU admission during current hospitalization\n* Diagnosis of acute kidney injury stage 3 according to KDIGO guidelines\n* RRT initiated no earlier than 3 days before or no later than 7 days after ICU admission\n\nExclusion Criteria:\n\n* Transfer from outside hospital with ongoing RRT\n* RRT exposure of less than 2 days (if CRRT or PD was provided) or less than 2 HD\u002FSLED sessions\n* Kidney failure (ESRD) patients on maintenance dialysis\n* Kidney transplant recipients\n* Previous or new diagnosis of glomerulonephritis","18 Years",{"count":258,"type":21},1000,"This is an international, multicenter, observational study aimed at investigating acute kidney injury requiring renal replacement therapy (AKI-RRT) in Latin American countries. The main questions this study aims to answer are:\n\n* What is the epidemiology, outcomes, and processes of care for patients with AKI-RRT in Latin America?\n* How do outcomes differ across different countries in Latin America?\n* What factors (demographics, clinical, socioeconomic) influence outcomes in patients with AKI-RRT in Latin America?\n\nThe main aims of this study are to:\n\n* Establish a comprehensive database containing clinical, laboratory, treatment, process, and outcome data of patients with AKI-RRT in Latin America\n* Describe current epidemiology of AKI-RRT in Latin America\n* Compare processes of care and outcomes across different countries in Latin America\n* Provide data resources to facilitate and promote clinical research in AKI-RRT",[261,262,263,264,265,266],"Dialysis","Critically Ill Acute Kidney Injury","Renal Replacement Therapy for Acute Kidney Injury in ICU","Acute Kidney Injury","Renal Replacement Therapy","AKI",[266,268,269,270,271,272,273,274],"ICU","RRT","Latin America","acute kidney injury","renal replacement therapy","intensive care unit","dialysis","2026-03-11",{"date":277,"type":33},"2026-03-12",{"date":279,"type":33},"2026-03-01",{"date":281,"type":21},"2027-06-30",{"name":283,"class":116},"University of Alabama at Birmingham",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":16,"sex":291,"minAge":292,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":22,"phases":294,"briefSummary":295,"conditions":296,"keywords":300,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":313},"100610280","implementation-of-screen-treat-and-triage-for-women-living-with-hiv-in-la-romana-istar-100610280","NCT07225530","Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)","(iSTAR)","Inclusion Criteria:\n\n* 25 years of age;\n* female sex assigned at birth (any gender identity);\n* HIV-positive;\n* women who have had cervical cancer precursor lesions which were removed more than 6 months ago; and\n* understand Spanish\n\nExclusion Criteria:\n\n* ages outside of the specified inclusion criteria;\n* women who are pregnant, less than 6 weeks postpartum, or in whom pregnancy cannot be excluded;\n* history of a Loop Electrosurgical Excision Procedure (LEEP) procedure in the last 6 months;\n* history of a hysterectomy;\n* previous diagnosis of gynecological cancer;\n* history of cancer of the anogenital tract; or\n* unable or unwilling to provide informed consent","FEMALE","25 Years",{"count":73,"type":21},[180],"This study aims to conduct a randomized controlled trial to evaluate the effectiveness of same-day HPV-based screen and treat among women living with HIV (WLH) in La Romana, Dominican Republic. With cervical cancer being a leading cause of cancer-related deaths in women living with HIV, and cervical cancer deaths being preventable through screening and early detection, this project seeks to identify factors associated with the successful implementation of the Screen, Triage, and Treat approach to inform future implementation and scale-up.",[297,298,299],"HIV Infections","HPV Infection","Cervical Cancer",[301,302,303,298],"People living with HIV (PLWH)","Cervical cancer screening","Spanish speakers","2026-02-24",{"date":306,"type":33},"2026-02-25",{"date":308,"type":33},"2026-02-23",{"date":310,"type":21},"2029-11-01",{"name":312,"class":116},"Columbia University",1,{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":17,"minAge":322,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":325,"conditions":326,"keywords":328,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":117},"100601920","serial-assessment-of-fertility-experiences-100601920","NCT07116772","Serial Assessment of Fertility Experiences","A Prospective Longitudinal Study of Growth, Development, Fertility and Reproductive Outcomes Among Adolescents and Young Adults With Sickle Cell Anemia With Hydroxyurea","SAFE","Inclusion Criteria:\n\n* Patients with documented sickle cell anemia (SCA).\n* At least 8 years of age at the time of enrollment.\n* Enrolled on the EXTEND or SACRED study.\n* Provide informed consent.\n* Able to take part in all parts of the study, including treatments, check-ups, and follow-up visits.\n\nExclusion Criteria:\n\n* Currently taking part in another treatment study (not EXTEND or SACRED).\n* Has received other treatments for sickle cell disease in the past 6 months.","8 Years",{"count":324,"type":21},250,"The SAFE study is a long-term research project that watches people with sickle cell anemia (SCA) over time. The main goal is to see how a medicine called hydroxyurea affects their growth, puberty, and ability to have children. A second goal is to see how hydroxyurea affects pregnancy outcomes, by comparing people who take the medicine to those who don't.",[327],"Sickle Cell Anemia",[329,330,210],"Hydroxyurea","Fertility","2026-02-03",{"date":333,"type":33},"2026-02-04",{"date":335,"type":33},"2023-07-10",{"date":337,"type":21},"2035-12-31",{"name":339,"class":116},"Children's Hospital Medical Center, Cincinnati",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":17,"minAge":347,"maxAge":204,"enrollmentInfo":348,"targetDuration":4,"studyType":22,"phases":350,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":366},"100361562","phase-4-a-safety-and-pharmacokinetics-study-of-idp-122-lotion-in-pediatric-participants-with-plaque-psoriasis-100361562","NCT03987763","A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis","A Phase 4, Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-122 Lotion in Pediatric Subjects With Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Is 6 to 16 years 11 months of age at time of informed consent\u002Fassent obtained.\n* Verbal and written informed consent\u002Fassent obtained from the participant and\u002For parent or legal guardian.\n* Has a clinical diagnosis of psoriasis at Screening and Baseline with an Investigator's Global Assessment (IGA) score of 3 or 4. The face, scalp, axillae, and intertriginous areas are to be excluded in this assessment, if psoriasis is present.\n* Has an area of plaque psoriasis appropriate for topical treatment that involves a BSA of at least 10% at Screening and Baseline. The face, scalp, axillae, and intertriginous areas are to be excluded in this calculation.\n* Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural and artificial) for the duration of the study.\n* Is in good general adrenal health, as determined by a 30-minute postcosyntropin stimulation serum cortisol level that is \\>18 μg\u002FdL at the Screening visit.\n* Females of childbearing potential and females who are pre-menses (9 years and older) must be willing to practice effective contraception for the duration of the study.\n\nExclusion Criteria:\n\n* Has a history of adrenal disease.\n* Presents with any concurrent skin condition that could interfere with the evaluation of the treatment areas, as determined by the Investigator.\n* Is pregnant, nursing an infant, or planning a pregnancy during the study period.\n* Has received treatment with any investigational drug or device within 60 days or 5 drug half-lives (whichever is longer) prior to baseline or is concurrently participating in another clinical study with an investigational drug or device.\n* Received treatment with a topical antipsoriatic drug product other than corticosteroids within 14 days prior to the Baseline visit and\u002For treatment containing corticosteroids within 28 days prior to the screening HPA axis stimulation test.\n* Has a history of hypersensitivity or allergic reaction to any of the study drug constituents.\n* Is considered by the Investigator, for any other reason, to be an unsuitable candidate for the study.","6 Years",{"count":349,"type":21},45,[351],"PHASE4","This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants with moderate to severe plaque psoriasis.",[354],"Psoriasis",[356],"Plaque psoriasis","2025-08-26",{"date":359,"type":33},"2025-08-27",{"date":361,"type":33},"2019-10-22",{"date":363,"type":21},"2026-06",{"name":365,"class":40},"Bausch Health Americas, Inc.",9,{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":11,"sex":17,"minAge":374,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":22,"phases":378,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":386,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":396},"100603534","quantitative-refractive-crosslinking-in-presbyopia-aged-patients-100603534","NCT07137767","Quantitative Refractive Crosslinking in Presbyopia Aged Patients","Quantitative Refractive Crosslinking in Presbyopia-Aged Patients: An Open Label, Multi-center, Phase I Study of the TECLens Corneal Crosslinking System for Correction of Refractive Error in Patients of Presbyopia Age","Inclusion Criteria:\n\n* Adults aged 40-65 years\n* Healthy cornea\n* Refractive error between +4.0 D and -5.0 D\n* Phakic or monofocal pseudophakic (≥6 months post IOL placement)\n* Visual acuity correctable by ±0.25 D\n\nExclusion Criteria:\n\n* Corneal dystrophy, scarring, or prior corneal crosslinking\n* Astigmatism \\>1.0 D\n* Active ocular infection, inflammation, or uncontrolled dry eye\n* Advanced glaucoma or diabetic retinopathy\n* History of delayed corneal healing\n* Pregnancy, breastfeeding, or planning pregnancy during study period\n* Certain medications (e.g., isotretinoin)\n* Recent participation in other investigational drug\u002Fdevice studies (within 30 days)\n* Patients with uncontrolled dry eye or surface disease","40 Years","65 Years",{"count":377,"type":21},25,[180],"An 'on-eye' UV delivery system for corneal crosslinking can be used safely and effectively to help free presbyopic patients from the need for reading glasses.",[381],"Presbyopia",[383,381,384,385],"Corneal crosslinking","Myopia","Hyperopia","NOT_YET_RECRUITING","2025-08-22",{"date":389,"type":33},"2025-08-29",{"date":391,"type":21},"2025-08-31",{"date":393,"type":21},"2026-08",{"name":395,"class":40},"TECLens, Inc.",2,{"id":398,"slug":399,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":17,"minAge":256,"maxAge":404,"enrollmentInfo":405,"targetDuration":4,"studyType":22,"phases":407,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":195},"100527790","safety-and-effectiveness-of-the-atc-system-in-the-treatment-of-acute-pe-100527790","NCT06152341","Safety and Effectiveness of the ATC System in the Treatment of Acute PE","Safety and Effectiveness of the ATC System in the Treatment of Acute Pulmonary Embolism","Inclusion Criteria:\n\n1. Patient is ≥ 18 and ≤ 90 years old\n2. Clinical signs and symptoms consistent with acute PE for \\\u003C 14 days\n3. CTA evidence of proximal PE\n4. RV\u002FLV ratio \\> 0.9\n5. Systolic BP ≥90 mmHg without the need for vasopressors\n6. Stable heart rate (HR) \\\u003C 130 BPM prior to procedure\n7. Patient is deemed medically eligible for interventional procedure(s), per investigator guidelines and clinical judgment\n8. Subject or legally authorized representative (LAR) is willing and able to provide written informed consent prior to receiving any non-standard of care protocol specific procedures\n\nExclusion Criteria:\n\n1. Prior PE \\\u003C 180 days from index procedure\n2. Thrombolytic use \\\u003C 30 days prior to baseline CTA\n3. Pulmonary hypertension with peak pulmonary artery systolic pressure (PASP) \\>70 mmHg by right heart catheterization\n4. FiO2 requirement \\>40% or \\>6 LPM to keep oxygen saturation \\>90%\n5. Hematocrit \\\u003C28%\n6. Platelets count \\\u003C100,000\u002FµL\n7. Serum creatinine \\>1.8 mg\u002FdL\n8. International normalized ratio (INR) \\>3\n9. Major trauma injury severity score (ISS) \\>15 prior to screening assessment\n10. Presence of intracardiac lead in right ventricle or atrium placed within 6 months prior to screening assessment\n11. Cardiovascular or pulmonary surgery within 7 days of index procedure\n12. Actively progressing cancer treated by chemotherapeutics\n13. Known bleeding diathesis or coagulation disorder\n14. Left bundle branch block\n15. History of severe or chronic pulmonary arterial hypertension\n16. History of chronic left heart disease with left ventricular ejection fraction ≤ 30%\n17. History of decompensated heart failure\n18. History of underlying lung disease that is oxygen dependent\n19. History of chest irradiation\n20. History of heparin-induced thrombocytopenia (HIT)\n21. Contraindication to systemic or therapeutic doses of anticoagulants\n22. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated\n23. Imaging evidence or other evidence that suggest, in the opinion of the investigator, the Subject is not appropriate for aspiration thrombectomy intervention\n24. Life expectancy \\\u003C90 days, as determined by investigator such as stage 4 cancer, frailty or severe COVID infections\n25. Female who is pregnant or nursing\n26. Current participation in another investigational drug or device treatment study.","90 Years",{"count":406,"type":21},30,[180],"This study is a prospective, single-arm, interventional, multicenter study to evaluate the safety and effectiveness of the ATC System in subjects with acute pulmonary embolism (PE).",[410],"Pulmonary Embolism Acute","2025-07-24",{"date":413,"type":33},"2025-07-28",{"date":415,"type":33},"2024-05-15",{"date":417,"type":21},"2025-09-15",{"name":419,"class":40},"Akura Medical",""]